Notably, the NeoADAURA trial—a phase III study—is investigating the efficacy and safety of neoadjuvant osimertinib, alone or in combination with chemotherapy, compared to chemotherapy alone in patients with resectable stage II–IIIB N2 EGFR-mutated NSCLC prior to surgery and adjuvant treatment [53]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.